- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
ISRN Cell Biology
Volume 2013 (2013), Article ID 135164, 14 pages
Integrin Signaling as a Cancer Drug Target
Division of Toxicology, LACDR, Leiden University, 2333 CC Leiden, The Netherlands
Received 11 June 2013; Accepted 9 July 2013
Academic Editors: D. Arnoult, G. Castoria, K. S. Echtay, and N. Zambrano
Copyright © 2013 Erik H. J. Danen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Integrins are transmembrane receptors that mediate cell adhesion to neighboring cells and to the extracellular matrix. Here, the various modes in which integrin-mediated adhesion regulates intracellular signaling pathways impinging on cell survival, proliferation, and differentiation are considered. Subsequently, evidence that integrins also control crucial signaling cascades in cancer cells is discussed. Lastly, the important role of integrin signaling in tumor cells as well as in stromal cells that support cancer growth, metastasis, and therapy resistance indicates that integrin signaling may be an attractive target for (combined) cancer therapy strategies. Current approaches to target integrins in this context are reviewed.
1. Integrin-Mediated Cell Adhesion
1.1. Cell Adhesion
Cells within multicellular organisms are typically attached to each other and to the extracellular matrix (ECM). ECM is a meshwork of various glycoproteins that exists in many forms, including laminin-rich basement membranes that align tissues, pliable matrices made from fibrilar networks of collagens, rigid collagen-based bone matrices, and provisional fibronectin-containing matrices associated with active processes such as wound healing and angiogenesis . Various adhesion molecules, such as those belonging to the cadherin family, mediate cell-cell contacts. Likewise, interactions with the ECM also occur through a variety of receptors, including syndecans, dystroglycans, and integrins.
Integrin cell adhesion receptors participate in cell-cell and cell-ECM interactions . This large family of heterodimeric transmembrane receptors recognizes a plethora of extracellular ligands, including transmembrane receptors on other cells and ECM proteins. The common integrin-binding motif, Arg-Gly-Asp (RGD), is shared by several ECM proteins, including fibronectin, vitronectin, and fibrinogen. Integrin binding to laminins and collagens occurs at other recognition motifs. Integrins participating in cell-cell adhesion bind counter receptors such as a disintegrin and metalloproteases (ADAMs), or immunoglobulin-type receptors such as intercellular adhesion molecules (ICAMs) and vascular cell adhesion molecules (VCAMs) that are expressed on leukocytes and endothelial cells.
1.3. Integrin Evolution
Clearly, integrins are essential receptors in mammalian development, and adult life. Studies in mice have attributed roles to certain integrins already at very early stages of development while others play specific roles later in the adult. In fact, integrins are found throughout metazoan evolution . In the nematode Caenorhabditis elegans, one β subunit (termed βpat3) and two α subunits (termed αina1 and αpat2) form two integrins. In the fruit fly Drosophila melanogaster, five integrins are formed through combination of one β subunit (termed βPS) with five α subunits (termed αPS1 through 5). The integrin family has expanded in vertebrates, and as many as 18 α and 8 β subunits have been identified in humans, from which 24 different functional integrins are formed.
1.4. Integrins: Transmembrane Linkers of Extra- and Intracellular Milieu
A unique feature of integrins that explains their critical role in cell adhesion is their ability to physically couple the extracellular ECM network to the intracellular cytoskeletal network . This involves connections at the very short integrin cytoplasmic tails with a complex of cytoskeletal adapter proteins. Importantly, this coupling is tightly regulated both at the level of integrin-mediated ligand binding as well as at the level of linkage to the cytoskeleton [5, 6]. This allows, for instance, muscle cells to anchor firmly to the tendon but platelets to start coagulation only when needed and leukocytes to temporarily attach to endothelial cells only when stimulated to extravasate.
2. Integrin Signaling
2.1. Bidirectional Signaling Controls Ligand-Cytoskeleton Coupling and Formation of Adhesion Plaques
Integrins act as bidirectional signaling molecules . Inside-out signaling refers to intracellular signaling pathways that regulate protein interactions at the cytoplasmic tails, which control integrin conformation and thereby affinity. Talins and kindlins are the major proteins that play critical roles in this process [5, 7, 8]. They bind to the integrin tails with their FERM domains, thereby separating the tails, which triggers a conformation change leading to integrin activation. Talin-integrin association can be regulated by disruption of intramolecular interactions within the talin molecule in response to intracellular signaling. For kindlins, modes of regulation are not understood, and the concerted action of these two regulators of integrin affinity also remains obscure. In addition, lateral diffusion and clustering of integrins can further adapt cell adhesion strength.
Vice versa, outside-in signaling refers to integrin-ligand binding and clustering affecting inter- and intramolecular interactions within the cluster of proteins associated at the integrin cytoplasmic tails and connecting to the cytoskeleton. Thus, following initial ligand binding of integrins, a growing adhesion plaque is formed through recruitment of more and more adaptor proteins and linkage to the cytoskeleton is strengthened . In the case of ECM adhesion, this plaque is called a “cell-matrix adhesion” . Such outside-in signaling does not happen when soluble ligands are bound but requires binding to immobilized ligands, for instance, ECM meshworks or receptors on opposing cells (although soluble ligands that cause clustering may suffice to trigger a limited signal).
2.2. Integrins Are Bidirectional Force Transmitters
Integrins and several associated cell-matrix adhesion proteins act as force sensors [10, 11]. A cascade of conformational changes in integrins and in associated proteins known to reside in cell-matrix adhesions, including focal adhesion kinase (FAK), p130Cas, vinculin, and others, is activated in response to force in either direction. Extracellular forces, through integrins, exert forces on integrin-associated cytoplasmic proteins, thereby exposing binding sites for new intramolecular interactions that drive a cytoskeletal stiffening response. Vice versa, cytoskeleton-generated forces, probably through similar conformational changes in the integrin-associated protein complex, allow integrins to pull and stretch ECM proteins such as fibronectin. This can cause ECM stiffening: exposure of binding sites driving, for instance, higher order interactions between fibronectin molecules during fibril formation or remodeling of collagen networks [12, 13]. Thus, integrins allow cells to maintain a balance between the intracellular cytoskeletal contractile machinery and ECM stiffness.
2.3. Activation of Biochemical Signaling Cascades
Outside-in signaling also involves the activation of kinases in response to integrin-mediated cell adhesion. For instance, the combination of lateral aggregation of integrins in the membrane and integrin ligand binding leads to recruitment and activation of FAK . This process is not entirely understood, but a conformational change leading to FERM domain displacement in FAK is involved [15, 16]. This change is associated with increased phosphorylation of tyrosine (Tyr)397, which along with an exposed PxxP motif forms a binding site for the Src homology 2 (SH2) and SH3 domains, respectively, of the Src kinase . Src then phosphorylates other tyrosines contributing to full activation of FAK. This active FAK/Src complex mediates a number of important signaling cascades downstream of integrins. Key examples include the control of the ERK MAP kinase pathway, the phosphatidylinositol-3 kinase (PI3K)/AKT pathway, and Rho GTPase activities.
Src can phosphorylate FAK at Tyr925, creating a binding site for the SH2 domain of Grb2 that links FAK to Sos, the guanine nucleotide exchange factor (GEF) for Ras . This is but one of the connections by which integrins can control activity of the Ras-Raf-MEK-ERK pathway. Src can also phosphorylate the scaffolding protein p130Cas that is associated with FAK via its SH3 domain, thereby creating a binding site for the adaptor protein Crk . The interaction with Crk, through association with Sos or through association with C3G, the GEF for Rap-1 that subsequently activates B-Raf, can result in ERK activation . Integrin-mediated adhesion also stimulates the association of the adaptor protein Nck with p130Cas, creating yet another potential link from p130Cas to ERK activation.
PI3K can also associate via the SH2 domain in its 85 kDa subunit with phosphorylated Tyr397 in FAK . Local activity of PI3K can contribute to various signaling pathways via its production of phosphatidylinositol-3,4,5-trisphosphate (PtdInsP3), including the membrane localization of Sos leading to ERK activation. Moreover, this pool of PtdInsP3 stimulates the recruitment of PKB/Akt to the membrane through its PH domain. This allows PDK1, which is also recruited to PtdInsP3 via its PH domain to activate PKB/Akt together with the elusive PDK2 through phosphorylation at Thr-308 and Ser-473, respectively .
Integrin-mediated activation of the FAK/Src complex also provides control of the activity of Rho family members . Rho small GTPases are critical regulators of cytoskeletal dynamics. The active FAK/Src complex recruits and phosphorylates p130Cas. Phosphorylated p130Cas recruits Dock180 and ELMO through its association with the adaptor protein Crk. The Dock180/ELMO complex acts as a guanine exchange factor (GEF) for Rac [24–26]. The Rac GTPase is important for Arp2/3-mediated branched F-actin growth that drives membrane protrusions in the form of lamellipodia. Alternatively, the FAK/Src complex phosphorylates another cell-matrix adhesion protein, paxillin, which recruits paxillin kinase linker (PKL) and Pak-interacting exchange factors (PIX), two GEFs for Rac and Cdc42 (another Rho GTPase that drives extension of filopodia, another type of membrane protrusions) [27, 28]. The FAK/Src complex also phosphorylates p190RhoGAP in cells adhering to fibronectin. This GTPase activating protein (GAP) suppresses RhoA GTP levels, thereby suppressing RhoA-mediated actin-myosin contractility and thus facilitating cell spreading upon adhesion to ECM [29, 30]. However, when external forces are applied to integrins, FAK cooperates with another Src family kinase, Fyn, to activate two GEFs for RhoA, LARG and GEFH1, to enhance cytoskeletal contractility, resulting in cellular stiffening . By coordinating the activities of Rho GTPases as described here, and at the same time recruiting components of the actin polymerization machinery such as Arp2/3, integrin-mediated adhesion complexes are signaling hotspots for local regulation of cytoskeletal dynamics.
2.4. Crosstalk with Other Receptors in Outside-in Signaling
The integrin-regulated signaling pathways described previously do not stand on their own but act in concert with signaling by other receptor classes. For instance, in cells adhering to fibronectin, activity of RhoA is controlled by engagement of integrin α5β1, which stimulates Src-mediated p190RhoGAP tyrosine phosphorylation, while syndecan-4 engagement stimulates PKCα-dependent translocation of p190RhoGAP to the cell membrane . In fact, a major part of integrin signaling may involve activation of pathways downstream of other receptors. One of the earliest examples for this notion came from studies investigating adhesion control of the Rac small GTPase. It turned out that epidermal growth factor receptor (EGFR) signaling was required to activate Rac in response to cell adhesion . In the case of growth factor receptors, the ability of integrins to cluster key enzymes and substrates may augment growth factor signaling through these same enzymes, including kinases and GTPases. However, it is now clear that integrin-mediated adhesion may lower the threshold for receptor tyrosine kinase (RTK) activation more directly. Integrins can associate with and/or trigger cross-phosphorylation of a large number of RTKs including EGFR, insulin-like growth factor (IGF)R, vascular endothelial growth factor (VEGF)R, platelet-derived growth factor (PDGF)R, c-Met, and macrophage stimulating 1 receptor (MST1R; Ron). Several studies have shown that Src family kinases mediate such integrin-RTK crosstalk [34–36].
Integrin-mediated adhesion to ECM can enhance growth factor signaling in yet another manner. Many growth factors bind to heparin and heparan sulfate found in ECM proteoglycans . Proteolytic cleavage of ECM proteins may liberate such growth factors (or ECM-derived peptides with signaling potential) for receptor binding and in some cases interactions with ECM are known to aid effective presentation of growth factors to their receptors. ECM proteins also contain growth factor-like motifs such as EGF themselves that may mimic soluble growth factor action . TGFβ is one of the growth factors associated with ECM proteins. In its inactive form, it is bound to and masked by the latency-associated peptide (LAP). Several αv integrins can bind to the RGD motif within LAP and cause exposure of active TGFβ, which can subsequently bind and activate TGFβR. Interestingly, this can occur through distinct protease-dependent or protease-independent mechanisms, the latter involving traction forces exerted through the integrin on the TGFβ-LAP complex by the actin cytoskeleton [38, 39].
2.5. Control of Signaling by Anchoring and Regulating the Cytoskeleton
Lastly, the ability of integrins to transmit forces, physically connect to the cytoskeleton, and act as cytoskeletal anchoring points as well as hotspots for dynamic regulation of the cytoskeleton can strongly impact on the cellular response to growth factors. Cytoskeletal tension allows cells to respond to mechanical forces with changes in gene transcription . This response can be mediated by altered concentrations of second messengers such as calcium and cyclic AMP and crosstalk with growth factor receptor signaling pathways as described earlier. More directly, the cytoskeleton is connected to integrins at the plasma membrane as well as to the nuclear envelope through linker of nucleoskeleton and cytoskeleton (LINC) complexes. Here, nesprin proteins in the outer membrane connect to microtubules, actin fibers, and intermediate filaments, while SUN proteins in the inner membrane bind the nuclear lamina . Thus, extracellular forces, through integrins, are mechanically linked to changes in nuclear orientation and shape . Since chromatin-binding proteins and DNA are attached to the nuclear lamina, extracellular mechanical stress may be propagated into the chromatin and affect gene expression through conformational regulation of DNA and associated proteins . At present, direct evidence for such purely mechanical coupling between ECM and gene expression is lacking.
3. Control of Cell Fate Decisions
The various modes of action discussed previously that allow integrins to regulate signaling pathways underlie adhesion control of cell survival, proliferation, and differentiation.
3.1. Cell Survival
Most cell types depend on integrin-mediated cell adhesion to ECM for survival and proliferation. Endothelial and epithelial cells rapidly undergo apoptosis when adhesion is disturbed. This process has been termed “anoikis.” The fact that integrin-mediated adhesion supports PI3K-mediated PKB/AKT activity is important in this respect [43, 44]. PKB/AKT activity is a key regulator of cell survival pathways. It phosphorylates/inhibits proapoptotic proteins such as Bad and procaspase-9 . PKB/AKT also suppresses proapoptotic transcriptional responses through Forkhead factors and p53 . Interestingly, integrins that are not ligand bound have been reported to stimulate apoptosis even in adherent cells by recruitment and activation of caspase-8 [47, 48]. This implies that the integrin expression profile must match the ECM environment to prevent cells from entering apoptosis.
FAK, besides contributing to PKB/AKT activity as described previously, can stimulate cell survival through enhanced expression of the antiapoptotic transcription factor NF-κB . Moreover, FAK protects against apoptosis by entering the nucleus, binding p53, and preventing p53-mediated transcription of proapoptotic genes . Notably, the link between integrin-mediated activation of FAK and this mechanism is unclear: FAK nuclear translocation is triggered by disruption of cell adhesion and is independent of its kinase activation. Perhaps, this represents a stress response allowing cells to cope with detachment, but the FAK:p53 interaction may not be important under adherent conditions.
3.2. Cell Proliferation
A major checkpoint in the cell cycle is the transition from G1 to S phase. Here, environmental cues drive cyclin-cdk activities that culminate in phosphorylation of the Rb tumor suppressor, which acts as a restriction point for entry in the S phase by sequestering the E2F transcription factor. Progression through the G1 phase depends on growth factor signaling but is also controlled by cell adhesion . Integrin-mediated attachment to ECM supports the sustained MAP kinase signaling that is required for transcription of cyclin D. The cyclin D-cdk4/6 activity leads to partial phosphorylation of the Rb-E2F complex resulting in E2F-mediated transcription of cyclin E. The cyclin E/Cdk2 activity leads to further phosphorylation of the Rb-E2F complex and E2F-mediated transcription of cyclin A and entry in S. Each of these events requires integrin-mediated attachment . Besides the transcriptional regulation of cyclin D through MAP kinase activity, adhesion-dependent activation of Rho GTPases also regulates levels and distribution of cdk inhibitors and cyclin D protein levels [53, 54]. FAK also plays an important role in adhesion control of cell proliferation: the ability of integrin-mediated adhesion to support cell cycle progression requires FAK activation .
3.3. Pluripotency and Differentiation
Integrin-mediated adhesion regulates the expression of genes associated with differentiation in several cell types. Differentiation of luminal epithelial cells in the mammary gland is impaired when β1 integrins are deleted [56, 57]. β1 integrin-mediated attachment to the basement membrane supports signaling through the prolactin receptor and Stat5 to transcribe milk genes . In the developing mammary gland, β1 integrin-mediated adhesion also controls basal-apical cell polarity, which is essential for lumen formation . In myoblasts, integrin-mediated attachment to ECM is also important for expression of desmin and meromyosin and for cell fusion to form contracting myotubes . It has also been shown that integrins can play important roles in restricting differentiation of skin keratinocytes to the suprabasal layers while promoting proliferation in the basal layer . Keratinocytes stop cycling and undergo rapid differentiation characterized by involucrin expression when detached in vitro. In vivo ablation of the various candidate integrins in keratinocytes indicates that general cell adhesion rather than signaling by a specific integrin is required to suppress differentiation in the basal layer of the skin .
Stem cells communicate with their microenvironment, “the niche” . The ECM is an intricate part of the niche, and integrin-ECM interactions allow locally embedded factors to support stemness . β1 integrin expression has been used as a marker for epithelial stem cell populations . In the gut, β1 integrins are required to compartmentalize intestinal epithelial stem cell proliferation and differentiation through effects on hedgehog signaling . In neuronal progenitors, β1 integrins coordinate Notch signaling, which is involved in cell fate decisions . Mammary gland stem cell self-renewal is supported by β1 integrins . Moreover, several studies show that integrins, in concert with cadherins, regulate centrosome positioning and spindle angle to control the balance between symmetrical and asymmetrical divisions, which is a key determinant of stem cell properties .
3.4. Force Transmission in Survival, Proliferation, and Differentiation Signaling
The important role for integrins in sensing of and responding to mechanical aspects of the environment may also explain their role in survival and proliferation signaling. Experiments using micropatterned substrates have shown that cell spreading and cytoskeletal tension rather than the number of integrin-ligand bonds control cell survival . Likewise, MAP kinase activity, cyclin D expression, and cdk inhibitor levels were not properly regulated when cells adhered to soft, rather than stiff collagen matrices leading these cells into quiescence . Again, the ability to generate cytoskeletal tension appeared crucial. On rigid but not soft ECM substrates, FAK is activated causing Rac-mediated cyclin D1 gene induction and cyclin D1-dependent Rb phosphorylation . ECM stiffness also controls angiogenesis in vitro and in vivo by Rho-dependent regulation of the balance between two mutually antagonistic transcription factors that influence expression of the VEGFR .
It has been demonstrated that physical properties of the ECM are decisive for lineage specification of mesenchymal stem cells. Soft substrates promote neuronal, and stiff substrates promote osteoblast lineages . There is some debate over what stem cells precisely “feel.” In experiments using hydrogels, stiffness also correlates with ECM protein anchorage point density. The increased resistance to integrin pulling as a result of this in stiffer matrices has been proposed to control stem cell lineage decisions . In either case, integrins will be crucial sensors of physical ECM properties in control of stem cell fate.
4. Integrin Expression and Function in Cancer
As discussed previously, integrins allow cells to sense chemical and physical information in their environment and can modulate cell signaling pathways and gene expression profiles in response to that. In doing so, integrins control cell survival, proliferation, and differentiation, which are disrupted from normal environmental control in cancer . One of the hallmarks of cancer cells is their ability to grow in an anchorage-independent fashion. They grow in vitro in semisolid media that do not support growth and lead to anoikis of nontransformed cells . Nevertheless, interactions with the surrounding ECM and neighboring cells also control cancer cell behavior. Numerous studies have shown that integrin expression profiles are subject to change during cancer growth and progression and that such changes contribute to the aggressive behavior of cancer cells [78–81]. Notably, besides tumor cell-autonomous functions, integrins also play important roles in processes in the tumor microenvironment that contribute significantly to tumor progression.
4.1. Roles for Tumor Cell Integrins
Transformation of rodent fibroblasts and kidney cells by Src or Ras oncogenes is associated with a decreased synthesis of fibronectin or a loss of the fibronectin receptor, integrin α5β1 [82, 83]. This plays a causal role in the oncogenic transformation: ectopic expression of α5β1 can restore fibronectin matrix assembly and suppress tumor formation in mice of transformed Chinese hamster ovary cells . This appears to reflect a relevant mechanism for human cancer as loss of the tumor suppressor p16INK4a prevents anoikis through downregulation of α5β1 expression levels . On the other hand, point mutants of the p53 tumor suppressor have been shown to stimulate invasion of cancer cells through enhanced trafficking of integrin α5β1 and EGFR . Thus, the role of α5β1 in cancer is context dependent, with distinct and even opposite effects on cancer growth or progression depending on the tumor suppressor or oncogene profile.
The role of αvβ6 in TGFβ activation may be important for epithelial-to-mesenchymal transitions (EMT) in cancer. Enhanced expression of this integrin is associated with EMT and poor prognosis in colon carcinoma . Crosstalk with TGFβ has also been reported for α6β4: transgenic suprabasal expression of α6β4 leads to inhibition of TGFβ signaling, which relieves TGFβ-mediated suppression of epithelial proliferation causing tumor growth . Indeed, expression of α6β4 is frequently enhanced in squamous cell carcinomas and correlates with poor prognosis in patients . Increased expression of α6β4 in breast cancer cells and secretion of its ECM ligand, laminin-5, support NFκB-mediated survival . In gastric carcinoma cells overexpressing the Met receptor, α6β4 can associate with and activate Met, which stimulates invasion and metastasis . α6β4 appears to play a dual role in growth and progression of squamous cell carcinomas: initial loss of α6β4 is associated with tumor growth in squamous cell carcinoma . During progression of skin cancer, α5β1 is unregulated . This switch from laminin-binding to fibronectin-binding integrins may facilitate detachment from the basement membrane and entry into the stromal compartment. A related switch occurs in melanoma progression when the radial growth phase converts to a vertical growth phase. This is associated with the induction of α5β1 and αvβ3 expression, and forced expression of αvβ3 is sufficient to trigger a conversion from radial to vertical growth [94, 95]. Enhanced matrix degradation through matrix metalloproteases may explain the effect of these integrins on the invasive growth of melanoma . Interestingly, individuals homozygous for an activating polymorphism in the β3 subunit have an increased risk to develop breast cancer, ovarian cancer, or melanoma, indicating that αvβ3 may involve those cancers as well . αvβ3 expression has also been implicated in bone metastasis in prostate and breast cancer patients [98–101]. One remarkably specific function of αvβ3 is relevant in the context of the Src oncogene: the β3 subunit cytoplasmic tail binds c-Src and supports its activation, which drives anchorage-independent growth and tumor formation (without effects on morphological Src-mediated transformation) in pancreatic and other cancers [102–104].
The ability of integrins to mediate tensional homeostasis may also be important in cancer. Increased cytoskeletal contractility through Rho GTPases in cancer cells can exert forces on ECM through integrins, resulting in environmental stiffening. A stiffer ECM in turn exerts forces on the cytoskeleton through integrins. This feed forward loop leading to increased tension may act as a driving force in cancer progression .
In melanoma, the expression of α4β1 correlates with tumor progression . This integrin may be important for tumor cell interactions with VCAM receptors on the endothelial cells allowing arrest and extravasation [107, 108]. Another integrin that has been associated specifically with metastasis is α2β1; forced expression of this integrin in rhabdomyosarcoma cells stimulated metastasis but did not affect primary tumor growth .
4.2. Lessons from Disruption of Integrin Signaling in Transgenic Mouse Models for Cancer
The role of the β1 family of integrins in cancer initiation, growth, and metastasis has been analyzed in transgenic mouse models. Studies using (conditional) genetic models point to critical roles for β1 integrins in initiation, growth, or progression of a variety of cancers (Table 1). In the context of the Polyoma middle T (PyMT) oncogene, deletion of β1 integrins essentially blocks breast cancer initiation, indicating that transformed cells require β1 integrins to survive. However, in the context of the ErbB2 oncogene, initiation is only delayed. Still, the role for integrin signaling is apparent, as these tumors are smaller, showing less angiogenesis and more apoptotic cells. As a consequence, metastasis to the lungs is drastically impaired. Interestingly, FAK/Src signaling and EGFR phosphorylation is impaired in these tumors. Likewise, in the RIPTag model for pancreatic cancer, deletion of β1 integrins leads to impaired tumor growth and metastasis, and deletion of the α2β1 integrin also impairs the outgrowth of squamous cell carcinomas. However, in other cancer models, β1 integrins appear to play a tumor suppressor-like role. Deletion of β1 integrins in the TRAMP prostate adenocarcinoma model led to more dramatic expansion of the tumor cell population, enhanced the rate of prostate tumor progression, and decreased overall animal survival . Also, the initiation and outgrowth of ErbB2/Neu-induced mammary tumors were not affected by α2β1 deletion, but intravasation and metastasis were increased . Taken together, β1 integrins can play remarkably distinct roles in tumor growth, progression, and metastasis depending on the model system. It will be important to understand the apparent metastasis suppressor activity that is conferred by integrins in certain contexts.
The major integrin-associated signal transducer that has been investigated in mouse models for cancer is FAK (Table 2). Four different studies have investigated the role of FAK in PyMT-induced breast cancer, and all four provide evidence that FAK plays an important role in primary tumor growth and progression. Tumor initiation, survival, and proliferation of tumor cells, maintenance of a cancer stem/progenitor cell population, and progression to carcinoma and metastasis are all supported by FAK. Likewise, FAK promotes the formation and growth of chemically induced skin cancer as well as its progression from papilloma to carcinoma.
4.3. Effects of Integrins in the Microenvironment
Importantly, integrin signaling not only regulates cancer growth and progression in a tumor cell autonomous fashion. Integrins on various cell types in the tumor microenvironment may be equally relevant. For instance, tumor angiogenesis is important for tumor growth and may be instrumental in the metastatic cascade for intravasation . As discussed previously, integrin-mediated adhesion provides endothelial cells with critical survival cues. Expression of αvβ3 and αvβ5 is induced on endothelial cells during angiogenesis. Based on studies using blocking antibodies, these integrins support the activities of distinct proangiogenic soluble factors . However, αv null embryos develop normally to E9.5 with extensive vasculogenesis and angiogenesis , and mice lacking αvβ3, αvβ5, or both show no defects in angiogenesis . In the context of cancer, tumor angiogenesis and tumor growth are in fact increased when wild type tumor cells are xenografted in αvβ3 knockout or αvβ3/αvβ5 double knockout mice, indicating that the blocking antibodies targeting these integrins may have acted as agonists [77, 116]. Interestingly, fewer tumor-infiltrating (but not circulating) macrophages are observed in the knockout mice, and bone marrow transplantation experiments indicate that the αv integrins are required for tumor suppression by macrophages .
Integrin α5β1 is also induced on angiogenic blood vessels, and its interaction with fibronectin supports angiogenesis . This same integrin may also play an important role on cancer-associated fibroblasts during invasion of squamous cell carcinomas. Fibroblasts remodel ECM to lay tracks along which carcinoma cells can invade the stroma and α5β1- and α3β1-mediated adhesion is important for Rho GTPase activity, contractility, and ECM remodeling . Besides regulating tumor invasion, cancer-associated fibroblasts also play important roles in tumor growth. In nonsmall cell lung cancer (NSCLC), α11β1 on these cells is needed to promote IGF2 expression, which in turn supports tumor growth .
The ability of αvβ6 and other RGD-binding integrins to control activation of TGFβ and TGFβR signaling may also impact tumor cells as well as cancer-associated fibroblasts. αvβ6 is upregulated at the tumor-stroma interface of various squamous cell carcinomas. Local αvβ6-mediated activation of TGFβ would inhibit proliferation of epithelial cells but also affect the complex interplay between carcinoma cells and stromal cells that control cancer progression . Another recent example of the important role of integrins in other cell types is seen in the remodeling that takes place in lymph nodes to accommodate homing and outgrowth of cancer cells. Tumor cells may create this “metastatic niche” by secreting VEGF, which reaches lymph nodes and locally stimulates lymphangiogenesis and PI3 K-mediated activation of integrin α4β1. Thus, an adhesive surface is created where disseminating tumor cells can home through their VCAM receptors and form metastatic colonies .
5. Current Clinical Use of Integrins as Targets for Anticancer Therapy
5.1. β1 and αv Integrins as Therapeutic Targets in Cancer
From what is mentioned earlier, it is evident that integrins and integrin signaling pathways may represent candidate targets to interfere with cancer growth and progression. Disrupting integrin-ligand interactions has the potential to interfere with key survival and proliferation signals that support cancer growth. Importantly, as discussed, integrin inhibition may simultaneously target key aspects of tumor cell behavior as well as crucial features of the tumor microenvironment such as angiogenesis or functions of cancer-associated fibroblasts that support cancer growth or invasion. Early studies showed that blocking a large subset of integrins, including α5β1, αvβ3, αvβ5, by using RGD peptides can interfere with tumor cell invasion in vitro and metastasis in mouse models . Subsequently, various synthetic peptides containing the RGD sequence or other integrin binding sequences, nonpeptide RGD mimetics, and disintegrins (integrin-binding proteins isolated from viper snake venoms) have been demonstrated to be able to block experimental tumor cell metastasis in animal model systems . Interestingly, similar approaches could at the same time inhibit tumor angiogenesis [130, 131]. Based on these initial promising findings, a variety of RGD-related peptides, peptides covering alternative integrin recognition motifs, nonpeptide mimetics, and humanized integrin-directed antibodies have been developed. These are in various stages of (pre) clinical testing or already on the market for a variety of diseases. In the context of cancer treatment, at present strategies for targeting β1 integrins or αv integrins have entered phase I, phase II, and even phase III clinical trials [132–134] (Table 3).
A humanized version of the LM609 anti-αvβ3 antibody, vitaxin, later developed into etaracizumab, was among the first to enter clinical testing. In Phase I and Phase II studies toxicity was low. Some signs of efficacy have been observed in melanoma and other solid tumors, but based on a randomized Phase II study where efficacy was compared to standard chemotherapy in metastatic melanoma, further clinical development appears to have been stopped [135–138]. CTNO 95, an αv antibody targeting αvβ3 as well as αvβ5, has also been tested in Phase I and showed little toxicity and some antitumor activity . The cyclic RGD peptide, cilengitide, selectively blocks αvβ3 and αvβ5. It has already gone through Phase I and Phase II trials for lung cancer, prostate cancer, and glioblastoma and is currently tested in Phase III for glioblastoma treatment [134, 140–143]. As discussed, such approaches targeting αv integrins may target tumor cells as well as the tumor microenvironment, for example, angiogenic vessels. Because of these potentially versatile effects, efficacy could be high, and further testing, for instance, with higher doses, seems worthwhile. On the other hand, this also means that the mode of action is poorly understood, and the apparent opposite results, for instance, of pharmaceutical inactivation and gene deletion in the case of αvβ3 and αvβ5 in the context of tumor angiogenesis remain puzzling [116, 122, 130]. Importantly, treatment with low-dose RGD peptides can actually cause enhanced VEGF-mediated angiogenesis and tumor growth , clearly indicating that the effects in patients can be unanticipated.
Another integrin that has emerged as a potential target for anticancer therapy is α5β1. Again, as discussed previously, this integrin plays important roles on tumor cells, cancer-associated fibroblasts, and angiogenic vessels. Based on the latter, a humanized antibody, volociximab, was developed as an antiangiogenic agent. In a Phase I trial, volociximab showed little toxicity in patients with solid tumors, and in two cases disease stabilization in response to treatment was observed . An interesting alternative means of targeting α5β1 makes use of the fact that this integrin requires a second recognition motif, in addition to RGD, for its interaction with fibronectin . ATN-161 was derived from this so-called “synergy sequence,” PHSRN and inhibits growth and metastasis in animal models [147, 148]. ATN-161 has been tested in a Phase I clinical trial where no dose-limiting toxicities occurred in patients with advanced solid tumors . Strikingly, one in three patients manifested prolonged stable disease in this study, clearly warranting further testing in Phase II trials.
5.2. Inhibition of FAK
Several FAK inhibitors have been developed and have entered cancer trials (Table 3). The FAK homologue, Pyk2, can compensate for lack or inhibition of FAK activity. Therefore, design of FAK inhibitors preferably leads to dual specificity compounds blocking both FAK and Pyk2. The early FAK-specific inhibitors, PF-573228 and NVP-TAC544 from Pfizer and Novartis, respectively, served as backbones for derivatives showing such dual specificity that are in early stages of clinical development. PF-562271 is an ATP-competitive, reversible inhibitor of catalytic activity of FAK and Pyk2. PF-562271 treatment led to dose- and drug exposure-dependent tumor regression in several human-mouse xenograft models without weight loss, morbidity, or mortality . This compound is in Phase I testing for various solid tumors, and initial results with respect to safety and sporadic cases of improved tumor-related symptoms appear promising . Another inhibitor is TAE-226 (Novartis) that was developed as a FAK inhibitor but also effectively inhibits IGF1R and is not in clinical development currently [152, 153]. Several other FAK/Pyk2 inhibitors are in Phase I testing. Like strategies targeting integrins, antitumor activity with FAK inhibitors may be due to effects on tumor cells or effects on other supporting cell types, such as endothelial cells. Moreover, although FAK is an important player in integrin signaling, effects of these inhibitors may be unrelated to the role of FAK in integrin adhesion complexes. Rather, FAK interacting physically and functionally with transcriptional regulators (e.g., p53) or RTKs (e.g., EGFR) may be the relevant target.
5.3. Combinatorial Treatment: Sensitization to Radio-, Chemo-, or Targeted Therapy
Ongoing clinical trials that further evaluate the potential of integrin-blocking strategies described previously usually do so in the context of chemo- or existing targeted therapy. This likely is the most successful application of peptides and antibodies targeting integrins: disrupting prosurvival and proliferation signals in tumor cells and other cell types in the tumor microenvironment that depend on integrin-mediated adhesion and thereby (i) weaken tumor cells directly (e.g., blocking tumor cell interactions with their environment) to render them more sensitive to other therapies, (ii) weaken tumor cells indirectly by corrupting essential input from the environment (e.g., loss of oxygenation by killing endothelial cells; loss of paracrine stimuli from stromal cells), and (iii) preventing therapy-induced responses in the microenvironment that protect tumor cells (e.g., blocking the enhanced αvβ3-mediated endothelial cell survival triggered by irradiation that would protect cancer cells through enhanced angiogenesis ).
Resistance to radio-, chemo-, or targeted therapies represents a major hurdle in cancer therapy. Disrupting adhesion signals that allow cancer cells to evade therapy may significantly improve therapy. Attachment in vitro of small cell lung cancer (SCLC) cells to two-dimensional ECM substrates containing proteins that typically surround SCLC tumors confers protection against apoptosis induced by doxorubicin, cyclophosphamide, and etoposide . This chemoprotective signal can be disrupted using β1 antibodies. ECM attachment also suppresses breast cancer cell apoptosis induced by paclitaxel and vincristine, and β1 antibodies sensitize to these microtubule disruptors that are commonly used in breast cancer therapy . Likewise, attachment of DU145 prostate cancer cells to fibronectin through β1 integrins protects against ceramide or docetaxel . The role of β1 integrins in determining chemosensitivity in 2D cultures appears context dependent: in Src-transformed cells expression of β1 integrins promotes sensitivity to cisplatin and other genotoxicants . β1 integrin-mediated ECM attachment also protects against radiation-induced genotoxic injury , and interfering with β1 integrins or specifically with α5β1 integrin-mediated adhesion can also enhance sensitivity to radiotherapy of different human cancer cell types grown in three-dimensional cultures or as xenografts in mice [160–162]. Also, ovarian cancer ascites has been shown to confer protection against TRAIL-induced apoptosis through integrin αvβ5 . Activities of FAK and PKB/AKT have been implicated in several of these integrin-mediated protective signaling pathways. Lastly, integrins have also been identified as potential targets for improved efficacy of targeted therapies: disruption of integrin-mediated laminin adhesion complexes that signal through FAK-sensitized ErbB2 positive breast cancer cells to trastuzumab and lapatinib, antibodies targeting the extracellular and kinase domains of ErbB2 .
6. Concluding Remarks
Integrins allow cells to interact with their local environment and translate external chemical and physical cues into a concerted intracellular response. A number of distinct connections have been described from integrin adhesion complexes to regulation of gene expression, including local concentration of enzymes and substrates to trigger intracellular signaling, harnessing signal transduction cascades downstream from other receptors, such as RTKs, and physical connections through cytoskeletal elements from integrins to the nucleus that may provide mechanical control of gene transcription. Together, such mechanisms govern cell survival, proliferation, and differentiation. Integrin signaling, like most signal transduction cascades, is typically rewired in cancer cells, but many studies have shown that integrins still regulate tumor growth, progression, and metastasis. Interfering with integrin-mediated attachment or preventing integrin signaling has the potential to disrupt key survival or proliferation cues both in tumor and tumor-associated cells including, for instance, endothelial cells. Altogether, this can lead to tumor shrinkage and increased sensitivity to existing radio-, chemo-, or targeted therapies. Studies using genetically engineered mice support this idea but also show that in some contexts integrins mediate tumor (metastasis) suppressive effects, indicating that use of integrin antagonists may trigger unwanted outcomes. Clearly, much more mechanistic insight is required to determine which integrin-blocking strategies may be applied to which types and stages of cancer. Nevertheless, initial promising results with integrin inhibitors in clinical trials warrant continued translation of findings obtained in cell culture systems to in vivo cancer models and testing in clinical trials. Ultimately, strategies will hopefully be designed where disruption of integrin signaling synergizes with genotoxic and/or other targeted antitumor strategies to effectively eradicate tumors.
Conflict of Interests
The author declares no direct financial relation with any commercial entities mentioned in the paper that might lead to a conflict of interests.
- R. O. Hynes, “The extracellular matrix: not just pretty fibrils,” Science, vol. 326, no. 5957, pp. 1216–1219, 2009.
- R. O. Hynes, “Integrins: bidirectional, allosteric signaling machines,” Cell, vol. 110, no. 6, pp. 673–687, 2002.
- R. O. Hynes and Q. Zhao, “The evolution of cell adhesion,” Journal of Cell Biology, vol. 150, no. 2, pp. F89–F95, 2000.
- C. Brakebusch and R. Fässler, “The integrin-actin connection, an eternal love affair,” The EMBO Journal, vol. 22, no. 10, pp. 2324–2333, 2003.
- M. Moser, K. R. Legate, R. Zent, and R. Fässler, “The tail of integrins, talin, and kindlins,” Science, vol. 324, no. 5929, pp. 895–899, 2009.
- B. Geiger, J. P. Spatz, and A. D. Bershadsky, “Environmental sensing through focal adhesions,” Nature Reviews Molecular Cell Biology, vol. 10, no. 1, pp. 21–33, 2009.
- S. Tadokoro, S. J. Shattil, K. Eto et al., “Talin binding to integrin β tails: a final common step in integrin activation,” Science, vol. 302, no. 5642, pp. 103–106, 2003.
- F. Ye, G. Hu, D. Taylor et al., “Recreation of the terminal events in physiological integrin activation,” Journal of Cell Biology, vol. 188, no. 1, pp. 157–173, 2010.
- B. Geiger, A. Bershadsky, R. Pankov, and K. M. Yamada, “Transmembrane extracellular matrix-cytoskeleton crosstalk,” Nature Reviews Molecular Cell Biology, vol. 2, no. 11, pp. 793–805, 2001.
- J. C. Friedland, M. H. Lee, and D. Boettiger, “Mechanically activated integrin switch controls α5β1 function,” Science, vol. 323, no. 5914, pp. 642–644, 2009.
- S. W. Moore, P. Roca-Cusachs, and M. P. Sheetz, “Stretchy proteins on stretchy substrates: the important elements of integrin-mediated rigidity sensing,” Developmental Cell, vol. 19, no. 2, pp. 194–206, 2010.
- E. Klotzsch, M. L. Smith, K. E. Kubow et al., “Fibronectin forms the most extensible biological fibers displaying switchable force-exposed cryptic binding sites,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 43, pp. 18267–18272, 2009.
- R. Kirmse, H. Otto, and T. Ludwig, “Interdependency of cell adhesion, force generation and extracellular proteolysis in matrix remodeling,” Journal of Cell Science, vol. 124, no. 11, pp. 1857–1866, 2011.
- T. Hato, N. Pampori, and S. J. Shattil, “Complementary roles for receptor clustering and conformational change in the adhesive and signaling functions of integrin ,” Journal of Cell Biology, vol. 141, no. 7, pp. 1685–1695, 1998.
- R. O. Jácamo and E. Rozengurt, “A truncated FAK lacking the FERM domain displays high catalytic activity but retains responsiveness to adhesion-mediated signals,” Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 1299–1304, 2005.
- D. Lietha, X. Cai, D. F. J. Ceccarelli, Y. Li, M. D. Schaller, and M. J. Eck, “Structural basis for the autoinhibition of focal adhesion kinase,” Cell, vol. 129, no. 6, pp. 1177–1187, 2007.
- D. D. Schlaepfer and T. Hunter, “Integrin signalling and tyrosine phosphorylation: just the FAKs?” Trends in Cell Biology, vol. 8, no. 4, pp. 151–157, 1998.
- D. D. Schlaepfer, S. K. Hanks, T. Hunter, and P. Van der Geer, “Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase,” Nature, vol. 372, no. 6508, pp. 786–791, 1994.
- K. Vuori, H. Hirai, S. Aizawa, and E. Ruoslahti, “Induction of p130cas signaling complex formation upon integrin-mediated cell adhesion: a role for Src family kinases,” Molecular and Cellular Biology, vol. 16, no. 6, pp. 2606–2613, 1996.
- D. D. Schlaepfer, C. R. Hauck, and D. J. Sieg, “Signaling through focal adhesion kinase,” Progress in Biophysics and Molecular Biology, vol. 71, no. 3-4, pp. 435–478, 1999.
- H.-C. Chen and J.-L. Guan, “Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 21, pp. 10148–10152, 1994.
- A. Khwaja, P. Rodriguez-Viciana, S. Wennström, P. H. Warne, and J. Downward, “Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway,” The EMBO Journal, vol. 16, no. 10, pp. 2783–2793, 1997.
- S. Huveneers and E. H. J. Danen, “Adhesion signaling—crosstalk between integrins, Src and Rho,” Journal of Cell Science, vol. 122, no. 8, pp. 1059–1069, 2009.
- E. Brugnera, L. Haney, C. Grimsley et al., “Unconventional Rac-GEF activity is mediated through the Dock180-ELMO complex,” Nature Cell Biology, vol. 4, no. 8, pp. 574–582, 2002.
- E. Kiyokawa, Y. Hashimoto, S. Kobayashi, H. Sugimura, T. Kurata, and M. Matsuda, “Activation of Rac1 by a Crk SH3-binding protein, DOCK180,” Genes and Development, vol. 12, no. 21, pp. 3331–3336, 1998.
- D. Chodniewicz and R. L. Klemke, “Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold,” Biochimica et Biophysica Acta, vol. 1692, no. 2-3, pp. 63–76, 2004.
- N. O. Deakin and C. E. Turner, “Paxillin comes of age,” Journal of Cell Science, vol. 121, no. 15, pp. 2435–2444, 2008.
- J. P. ten Klooster, Z. M. Jaffer, J. Chernoff, and P. L. Hordijk, “Targeting and activation of Rac1 are mediated by the exchange factor β-Pix,” Journal of Cell Biology, vol. 172, no. 5, pp. 759–769, 2006.
- W. T. Arthur, L. A. Petch, and K. Burridge, “Integrin engagement suppresses RhoA activity via a c-Src-dependent mechanism,” Current Biology, vol. 10, no. 12, pp. 719–722, 2000.
- X.-D. Ren, W. B. Kiosses, D. J. Sieg, C. A. Otey, D. D. Schlaepfer, and M. A. Schwartz, “Focal adhesion kinase suppresses Rho activity to promote focal adhesion,” Journal of Cell Science, vol. 113, no. 20, pp. 3673–3678, 2000.
- C. Guilluy, V. Swaminathan, R. Garcia-Mata, E. T. O'Brien, R. Superfine, and K. Burridge, “The Rho GEFs LARG and GEF-H1 regulate the mechanical response to force on integrins,” Nature Cell Biology, vol. 13, no. 6, pp. 722–728, 2011.
- M. D. Bass, M. R. Morgan, K. A. Roach, J. Settleman, A. B. Goryachev, and M. J. Humphries, “p190RhoGAP is the convergence point of adhesion signals from α5β1 integrin and syndecan-4,” Journal of Cell Biology, vol. 181, no. 6, pp. 1013–1026, 2008.
- N. Marcoux and K. Vuori, “EGF receptor mediates adhesion-dependent activation of the Rac GTPase: a role for phosphatidylinositol 3-kinase and Vav2,” Oncogene, vol. 22, no. 38, pp. 6100–6106, 2003.
- K. M. Yamada and S. Even-Ram, “Integrin regulation of growth factor receptors,” Nature Cell Biology, vol. 4, no. 4, pp. E75–E76, 2002.
- M. A. Schwartz, “Integrin signaling revisited,” Trends in Cell Biology, vol. 11, no. 12, pp. 466–470, 2001.
- L. Moro, L. Dolce, S. Cabodi et al., “Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines,” Journal of Biological Chemistry, vol. 277, no. 11, pp. 9405–9414, 2002.
- G. Panayotou, P. End, M. Aumailley, R. Timpl, and J. Engel, “Domains of laminin with growth-factor activity,” Cell, vol. 56, no. 1, pp. 93–101, 1989.
- J. S. Munger, X. Huang, H. Kawakatsu et al., “The integrin binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis,” Cell, vol. 96, no. 3, pp. 319–328, 1999.
- J. S. Munger and D. Sheppard, “Cross talk among TGF-beta signaling pathways, integrins, and the extracellular matrix,” Cold Spring Harbor Perspectives in Biology, vol. 3, Article ID a005017, 2011.
- D. E. Ingber, “Tensegrity: the architectural basis of cellular mechanotransduction,” Annual Review of Physiology, vol. 59, pp. 575–599, 1997.
- R. P. Martins, J. D. Finan, F. Guilak, and D. A. Lee, “Mechanical regulation of nuclear structure and function,” Annual Review of Biomedical Engineering, vol. 14, pp. 431–455, 2012.
- A. J. Maniotis, C. S. Chen, and D. E. Ingber, “Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stabilize nuclear structure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 3, pp. 849–854, 1997.
- S. M. Frisch and E. Ruoslahti, “Integrins and anoikis,” Current Opinion in Cell Biology, vol. 9, no. 5, pp. 701–706, 1997.
- S. M. Frisch and R. A. Screaton, “Anoikis mechanisms,” Current Opinion in Cell Biology, vol. 13, no. 5, pp. 555–562, 2001.
- S. G. Kennedy, A. J. Wagner, S. D. Conzen et al., “The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal,” Genes and Development, vol. 11, no. 6, pp. 701–713, 1997.
- J. Downward, “PI 3-kinase, Akt and cell survival,” Seminars in Cell and Developmental Biology, vol. 15, no. 2, pp. 177–182, 2004.
- J. A. Varner, D. A. Emerson, and R. L. Juliano, “Integrin α5β1 expression negatively regulates cell growth: reversal by attachment to fibronectin,” Molecular Biology of the Cell, vol. 6, no. 6, pp. 725–740, 1995.
- D. G. Stupack, X. S. Puente, S. Boutsaboualoy, C. M. Storgard, and D. A. Cheresh, “Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins,” Journal of Cell Biology, vol. 155, no. 4, pp. 459–470, 2001.
- D. Huang, M. Khoe, M. Befekadu et al., “Focal adhesion kinase mediates cell survival via NF-κB and ERK signaling pathways,” American Journal of Physiology, vol. 292, no. 4, pp. C1339–C1352, 2007.
- S.-T. Lim, X. L. Chen, Y. Lim et al., “Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation,” Molecular Cell, vol. 29, no. 1, pp. 9–22, 2008.
- E. H. Danen and K. M. Yamada, “Fibronectin, integrins, and growth control,” Journal of Cellular Physiology, vol. 189, pp. 1–13, 2001.
- X. Zhu, M. Ohtsubo, R. M. Böhmer, J. M. Roberts, and R. K. Assoian, “Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein,” Journal of Cell Biology, vol. 133, no. 2, pp. 391–403, 1996.
- E. H. J. Danen, P. Sonneveld, A. Sonnenberg, and K. M. Yamada, “Dual stimulation of Ras/Mitogen-activated protein kinase and RhoA by cell adhesion to fibronectin supports growth factor-stimulated cell cycle progression,” Journal of Cell Biology, vol. 151, no. 7, pp. 1413–1422, 2000.
- A. Mettouchi, S. Klein, W. Guo et al., “Integrin-specific activation of Rac controls progression through the G1 phase of the cell cycle,” Molecular Cell, vol. 8, no. 1, pp. 115–127, 2001.
- P. Wang, C. Ballestrem, and C. H. Streuli, “The C terminus of talin links integrins to cell cycle progression,” The Journal of Cell Biology, vol. 195, no. 3, pp. 499–513, 2011.
- N. Li, Y. Zhang, M. J. Naylor et al., “β1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli,” The EMBO Journal, vol. 24, no. 11, pp. 1942–1953, 2005.
- M. J. Naylor, N. Li, J. Cheung et al., “Ablation of β1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation,” Journal of Cell Biology, vol. 171, no. 4, pp. 717–728, 2005.
- R. Xu, C. M. Nelson, J. L. Muschler, M. Veiseh, B. K. Vonderhaar, and M. J. Bissell, “Sustained activation of STAT5 is essential for chromatin remodeling and maintenance of mammary-specifi c function,” Journal of Cell Biology, vol. 184, no. 1, pp. 57–66, 2009.
- N. Akhtar and C. H. Streuli, “An integrin-ILK-microtubule network orients cell polarity and lumen formation in glandular epithelium,” Nature Cell Biology, vol. 15, pp. 17–27, 2013.
- A. S. Menko and D. Boettiger, “Occupation of the extracellular matrix receptor, integrin, is a control point for myogenic differentiation,” Cell, vol. 51, no. 1, pp. 51–57, 1987.
- F. M. Watt, “Role of integrins in regulating epidermal adhesion, growth and differentiation,” The EMBO Journal, vol. 21, no. 15, pp. 3919–3926, 2002.
- C. Margadant, R. A. Charafeddine, and A. Sonnenberg, “Unique and redundant functions of integrins in the epidermis,” FASEB Journal, vol. 24, no. 11, pp. 4133–4152, 2010.
- F. M. Watt and B. L. M. Hogan, “Out of eden: stem cells and their niches,” Science, vol. 287, no. 5457, pp. 1427–1430, 2000.
- A. Kerever, J. Schnack, D. Vellinga et al., “Novel extracellular matrix structures in the neural stem cell niche capture the neurogenic factor fibroblast growth factor 2 from the extracellular milieu,” Stem Cells, vol. 25, no. 9, pp. 2146–2157, 2007.
- P. H. Jones and F. M. Watt, “Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression,” Cell, vol. 73, no. 4, pp. 713–724, 1993.
- R. G. Jones, X. Li, P. D. Gray et al., “Conditional deletion of β1 integrins in the intestinal epithelium causes a loss of Hedgehog expression, intestinal hyperplasia, and early postnatal lethality,” Journal of Cell Biology, vol. 175, no. 3, pp. 505–514, 2006.
- L. S. Campos, L. Decker, V. Taylor, and W. Skarnes, “Notch, epidermal growth factor receptor, and β1-integrin pathways are coordinated in neural stem cells,” Journal of Biological Chemistry, vol. 281, no. 8, pp. 5300–5309, 2006.
- I. Taddei, M.-A. Deugnier, M. M. Faraldo et al., “β1 Integrin deletion from the basal compartment of the mammary epithelium affects stem cells,” Nature Cell Biology, vol. 10, no. 6, pp. 716–722, 2008.
- V. Marthiens, I. Kazanis, L. Moss, K. Long, and C. Ffrench-Constant, “Adhesion molecules in the stem cell niche—more than just staying in shape?” Journal of Cell Science, vol. 123, no. 10, pp. 1613–1622, 2010.
- C. S. Chen, M. Mrksich, S. Huang, G. M. Whitesides, and D. E. Ingber, “Geometric control of cell life and death,” Science, vol. 276, no. 5317, pp. 1425–1428, 1997.
- J. Fringer and F. Grinnell, “Fibroblast quiescence in floating or released collagen matrices: contribution of the ERK signaling pathway and actin cytoskeletal organization,” Journal of Biological Chemistry, vol. 276, no. 33, pp. 31047–31052, 2001.
- E. A. Klein, L. Yin, D. Kothapalli et al., “Cell-cycle control by physiological matrix elasticity and in vivo tissue stiffening,” Current Biology, vol. 19, no. 18, pp. 1511–1518, 2009.
- A. Mammoto, K. M. Connor, T. Mammoto et al., “A mechanosensitive transcriptional mechanism that controls angiogenesis,” Nature, vol. 457, no. 7233, pp. 1103–1108, 2009.
- A. J. Engler, S. Sen, H. L. Sweeney, and D. E. Discher, “Matrix elasticity directs stem cell lineage specification,” Cell, vol. 126, no. 4, pp. 677–689, 2006.
- B. Trappmann, J. E. Gautrot, J. T. Connelly et al., “Extracellular-matrix tethering regulates stem-cell fate,” Nature Materials, vol. 11, pp. 642–649, 2012.
- D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000.
- D. Taverna, H. Moher, D. Crowley, L. Borsig, A. Varki, and R. O. Hynes, “Increased primary tumor growth in mice null for β3- or β3/β5-integrins or selectins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 3, pp. 763–768, 2004.
- G. J. Mizejewski, “Role of integrins in cancer: survey of expression patterns,” Proceedings of the Society for Experimental Biology and Medicine, vol. 222, no. 2, pp. 124–138, 1999.
- E. H. J. Danen, “Integrins: regulators of tissue function and cancer progression,” Current Pharmaceutical Design, vol. 11, no. 7, pp. 881–891, 2005.
- E. H. J. Danen and A. Sonnenberg, “Integrins in regulation of tissue development and function,” The Journal of pathology, vol. 201, no. 4, pp. 632–641, 2003.
- W. Guo and F. G. Giancotti, “Integrin signalling during tumour progression,” Nature Reviews Molecular Cell Biology, vol. 5, no. 10, pp. 816–826, 2004.
- K. Olden and K. M. Yamada, “Mechanism of the decrease in the major cell surface protein of chick embryo fibroblasts after transformation,” Cell, vol. 11, no. 4, pp. 957–969, 1977.
- L. C. Plantefaber and R. O. Hynes, “Changes in integrin receptors on oncogenically transformed cells,” Cell, vol. 56, no. 2, pp. 281–290, 1989.
- F. G. Giancotti and E. Ruoslahti, “Elevated levels of the α5β1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells,” Cell, vol. 60, no. 5, pp. 849–859, 1990.
- T. Plath, K. Detjen, M. Welzel et al., “A novel function for the tumor suppressor : induction of anoikis via upregulation of the α5β1 fibronectin receptor,” Journal of Cell Biology, vol. 150, no. 6, pp. 1467–1477, 2000.
- P. A. J. Muller, P. T. Caswell, B. Doyle et al., “Mutant p53 drives invasion by promoting integrin recycling,” Cell, vol. 139, no. 7, pp. 1327–1341, 2009.
- R. C. Bates, D. I. Bellovin, C. Brown et al., “Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma,” Journal of Clinical Investigation, vol. 115, no. 2, pp. 339–347, 2005.
- D. M. Owens, M. R. Romero, C. Gardner, and F. M. Watt, “Suprabasal α6β4 integrin expression in epidermis results in enhanced tumourigenesis and disruption of TGFβ signalling,” Journal of Cell Science, vol. 116, no. 18, pp. 3783–3791, 2003.
- C. Van Waes, K. F. Kozarsky, A. B. Warren et al., “The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin α6β4,” Cancer Research, vol. 51, no. 9, pp. 2395–2402, 1991.
- V. M. Weaver, S. Lelièvre, J. N. Lakins et al., “β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium,” Cancer Cell, vol. 2, no. 3, pp. 205–216, 2002.
- L. Trusolino, A. Bertotti, and P. M. Comoglio, “A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth,” Cell, vol. 107, no. 5, pp. 643–654, 2001.
- C. S. Downer, F. M. Watt, and P. M. Speight, “Loss of α6 and β4 integrin subunits coincides with loss of basement membrane components in oral squamous cell carcinomas,” Journal of Pathology, vol. 171, no. 3, pp. 183–190, 1993.
- M. Gomez and A. Cano, “Expression of β1 integrin receptors in transformed mouse epidermal keratinocytes: upregulation of α5β1 in spindle carcinoma cells,” Molecular Carcinogenesis, vol. 12, no. 3, pp. 153–165, 1995.
- E. H. J. Danen, G. N. P. van Muijen, and D. J. Ruiter, “Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma,” Cancer Surveys, vol. 24, pp. 43–65, 1995.
- M.-Y. Hsu, D.-T. Shih, F. E. Meier et al., “Adenoviral gene transfer of β3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma,” American Journal of Pathology, vol. 153, no. 5, pp. 1435–1442, 1998.
- R. E. B. Seftor, E. A. Seftor, W. G. Stetler-Stevenson, and M. J. C. Hendrix, “The 72 kDa type IV collagenase is modulated via differential expression of and α5β1 integrins during human melanoma cell invasion,” Cancer Research, vol. 53, no. 14, pp. 3411–3415, 1993.
- S. E. Bojesen, A. Tybjærg-Hansen, and B. G. Nordestgaard, “Integrin β3 Leu33Pro homozygosity and risk of cancer,” Journal of the National Cancer Institute, vol. 95, no. 15, pp. 1150–1157, 2003.
- B. Felding-Habermann, T. E. O'Toole, J. W. Smith et al., “Integrin activation controls metastasis in human breast cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 4, pp. 1853–1858, 2001.
- S. Takayama, S. Ishii, T. Ikeda, S. Masamura, M. Doi, and M. Kitajima, “The relationship between bone metastasis from human breast cancer and integrin expression,” Anticancer Research, vol. 25, no. 1A, pp. 79–83, 2005.
- C. van den Hoogen, G. van der Horst, H. Cheung, J. T. Buijs, R. C. M. Pelger, and G. van der Pluijm, “Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer,” American Journal of Pathology, vol. 179, no. 5, pp. 2559–2568, 2011.
- N. P. McCabe, S. De, A. Vasanji, J. Brainard, and T. V. Byzova, “Prostate cancer specific integrin modulates bone metastatic growth and tissue remodeling,” Oncogene, vol. 26, no. 42, pp. 6238–6243, 2007.
- S. Huveneers, I. Van Den Bout, P. Sonneveld, A. Sancho, A. Sonnenberg, and E. H. J. Danen, “Integrin controls activity and oncogenic potential of primed c-Src,” Cancer Research, vol. 67, no. 6, pp. 2693–2700, 2007.
- J. S. Desgrosellier, L. A. Barnes, D. J. Shields et al., “An integrin -c-Src oncogenic unit promotes anchorage-independence and tumor progression,” Nature Medicine, vol. 15, no. 10, pp. 1163–1169, 2009.
- S. Huveneers, S. Arslan, B. Van De Water, A. Sonnenberg, and E. H. J. Danen, “Integrins uncouple Src-induced morphological and oncogenic transformation,” Journal of Biological Chemistry, vol. 283, no. 19, pp. 13243–13251, 2008.
- K. R. Levental, H. Yu, L. Kass et al., “Matrix crosslinking forces tumor progression by enhancing integrin signaling,” Cell, vol. 139, no. 5, pp. 891–906, 2009.
- B. Bierie and H. L. Moses, “Tumour microenvironment-GFΒ: the molecular Jekyll and Hyde of cancer,” Nature Reviews Cancer, vol. 6, no. 7, pp. 506–520, 2006.
- G. E. Rice and M. P. Bevilacqua, “An inducible endothelial cell surface glycoprotein mediates melanoma adhesion,” Science, vol. 246, no. 4935, pp. 1303–1306, 1989.
- H. Okahara, H. Yagita, K. Miyake, and K. Okumura, “Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) in tumor necrosis factor α enhancement of experimental metastasis,” Cancer Research, vol. 54, no. 12, pp. 3233–3236, 1994.
- B. M. C. Chan, N. Matsuura, Y. Takada, B. R. Zetter, and M. E. Hemler, “In vitro and in vivo consequences of VLA-2 expression on rhabdomyosarcoma cells,” Science, vol. 251, no. 5001, pp. 1600–1602, 1991.
- K. Moran-Jones, A. Ledger, and M. J. Naylor, “β1 integrin deletion enhances progression of prostate cancer in the TRAMP mouse model,” Scientific Reports, vol. 2, p. 526, 2012.
- N. E. Ramirez, Z. Zhang, A. Madamanchi et al., “The α2β1 integrin is a metastasis suppressor in mouse models and human cancer,” Journal of Clinical Investigation, vol. 121, no. 1, pp. 226–237, 2011.
- D. E. White, N. A. Kurpios, D. Zuo et al., “Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction,” Cancer Cell, vol. 6, no. 2, pp. 159–170, 2004.
- L. Huck, S. M. Pontier, D. M. Zuo, and W. J. Muller, “β1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 35, pp. 15559–15564, 2010.
- T. Tran, B. Barlow, L. O'Rear et al., “Loss of the α2β1 integrin alters human papilloma virus-induced squamous carcinoma progression in vivo and in vitro,” PLoS ONE, vol. 6, no. 10, Article ID e26858, 2011.
- A. Kren, V. Baeriswyl, F. Lehembre et al., “Increased tumor cell dissemination and cellular senescence in the absence of β1-integrin function,” The EMBO Journal, vol. 26, no. 12, pp. 2832–2842, 2007.
- L. E. Reynolds, L. Wyder, J. C. Lively et al., “Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins,” Nature Medicine, vol. 8, no. 1, pp. 27–34, 2002.
- P. P. Provenzano, D. R. Inman, K. W. Eliceiri, H. E. Beggs, and P. J. Keely, “Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer,” American Journal of Pathology, vol. 173, no. 5, pp. 1551–1565, 2008.
- H. Lahlou, V. Sanguin-Gendreau, D. Zuo et al., “Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 51, pp. 20302–20307, 2007.
- M. Luo, H. Fan, T. Nagy et al., “Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells,” Cancer Research, vol. 69, no. 2, pp. 466–474, 2009.
- Y. Pylayeva, K. M. Gillen, W. Gerald, H. E. Beggs, L. F. Reichardt, and F. G. Giancotti, “Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling,” Journal of Clinical Investigation, vol. 119, no. 2, pp. 252–266, 2009.
- G. W. McLean, N. H. Komiyama, B. Serrels et al., “Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression,” Genes and Development, vol. 18, no. 24, pp. 2998–3003, 2004.
- M. Friedlander, P. C. Brooks, R. W. Shaffer, C. M. Kincaid, J. A. Varner, and D. A. Cheresh, “Definition of two angiogenic pathways by distinct integrins,” Science, vol. 270, no. 5241, pp. 1500–1502, 1995.
- B. Bader, H. Rayburn, D. Crowley, and R. O. Hynes, “Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all integrins,” Cell, vol. 95, no. 4, pp. 507–519, 1998.
- S. Kim, K. Bell, S. A. Mousa, and J. A. Varner, “Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin,” American Journal of Pathology, vol. 156, no. 4, pp. 1345–1362, 2000.
- C. Gaggioli, S. Hooper, C. Hidalgo-Carcedo et al., “Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells,” Nature Cell Biology, vol. 9, no. 12, pp. 1392–1400, 2007.
- C.-Q. Zhu, S. N. Popova, E. R. S. Brown et al., “Integrin α11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 28, pp. 11754–11759, 2007.
- B. Garmy-Susini, C. J. Avraamides, J. S. Desgrosellier et al., “PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 22, pp. 9042–9047, 2013.
- M. J. Humphries, K. Olden, and K. M. Yamada, “A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells,” Science, vol. 233, no. 4762, pp. 467–470, 1986.
- G. P. Curley, H. Blum, and M. J. Humphries, “Integrin antagonists,” Cellular and Molecular Life Sciences, vol. 56, no. 5-6, pp. 427–441, 1999.
- P. C. Brooks, S. Stromblad, R. Klemke, D. Visscher, F. H. Sarkar, and D. A. Cheresh, “Antiintegrin blocks human breast cancer growth and angiogenesis in human skin,” Journal of Clinical Investigation, vol. 96, no. 4, pp. 1815–1822, 1995.
- R. Kerbel and J. Folkman, “Clinical translation of angiogenesis inhibitors,” Nature Reviews Cancer, vol. 2, no. 10, pp. 727–739, 2002.
- S. Hehlgans, M. Haase, and N. Cordes, “Signalling via integrins: implications for cell survival and anticancer strategies,” Biochimica et Biophysica Acta, vol. 1775, no. 1, pp. 163–180, 2007.
- D. Cox, M. Brennan, and N. Moran, “Integrins as therapeutic targets: lessons and opportunities,” Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 804–820, 2010.
- J. S. Desgrosellier and D. A. Cheresh, “Integrins in cancer: biological implications and therapeutic opportunities,” Nature Reviews Cancer, vol. 10, no. 1, pp. 9–22, 2010.
- J. C. Gutheil, T. N. Campbell, P. R. Pierce et al., “Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin ,” Clinical Cancer Research, vol. 6, no. 8, pp. 3056–3061, 2000.
- C. Delbaldo, E. Raymond, K. Vera et al., “Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against integrin receptor, in patients with advanced solid tumors,” Investigational New Drugs, vol. 26, no. 1, pp. 35–43, 2008.
- D. G. McNeel, J. Eickhoff, F. T. Lee et al., “Phase I trial of a monoclonal antibody specific for integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion,” Clinical Cancer Research, vol. 11, no. 21, pp. 7851–7860, 2005.
- P. Hersey, J. Sosman, S. O'Day et al., “A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin , ± dacarbazine in patients with stage IV metastatic melanoma,” Cancer, vol. 116, no. 6, pp. 1526–1534, 2010.
- S. A. Mullamitha, N. C. Ton, G. J. M. Parker et al., “Phase I evaluation of a fully human anti- integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors,” Clinical Cancer Research, vol. 13, no. 7, pp. 2128–2135, 2007.
- K. W. Beekman, A. D. Colevas, K. Cooney et al., “Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design,” Clinical Genitourinary Cancer, vol. 4, no. 4, pp. 299–302, 2006.
- L. B. Nabors, T. Mikkelsen, S. S. Rosenfeld et al., “Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1651–1657, 2007.
- D. A. Reardon, K. L. Fink, T. Mikkelsen et al., “Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme,” Journal of Clinical Oncology, vol. 26, no. 34, pp. 5610–5617, 2008.
- T. J. MacDonald, C. F. Stewart, M. Kocak et al., “Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 919–924, 2008.
- A. R. Reynolds, I. R. Hart, A. R. Watson et al., “Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors,” Nature Medicine, vol. 15, no. 4, pp. 392–400, 2009.
- A. D. Ricart, A. W. Tolcher, G. Liu et al., “Volociximab, a chimeric monoclonal antibody that specifically binds α5β1 integrin: a phase l, pharmacokinetic, and biological correlative study,” Clinical Cancer Research, vol. 14, no. 23, pp. 7924–7929, 2008.
- E. H. J. Danen, S.-I. Aota, A. A. van Kraats, K. M. Yamada, D. J. Ruiter, and G. N. P. Van Muijen, “Requirement for the synergy site for cell adhesion to fibronectin depends on the activation state of integrin α5β1,” Journal of Biological Chemistry, vol. 270, no. 37, pp. 21612–21618, 1995.
- P. Khalili, A. Arakelian, G. Chen et al., “A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo,” Molecular Cancer Therapeutics, vol. 5, no. 9, pp. 2271–2280, 2006.
- D. L. Livant, R. K. Brabec, K. J. Pienta et al., “Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma,” Cancer Research, vol. 60, no. 2, pp. 309–320, 2000.
- M. E. Cianfrocca, K. A. Kimmel, J. Gallo et al., “Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours,” British Journal of Cancer, vol. 94, no. 11, pp. 1621–1626, 2006.
- W. G. Roberts, E. Ung, P. Whalen et al., “Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271,” Cancer Research, vol. 68, no. 6, pp. 1935–1944, 2008.
- A. Schultze and W. Fiedler, “Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer,” Expert Opinion on Investigational Drugs, vol. 19, no. 6, pp. 777–788, 2010.
- J. Halder, Y. G. Lin, W. M. Merritt et al., “Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma,” Cancer Research, vol. 67, no. 22, pp. 10976–10983, 2007.
- V. G. Brunton and M. C. Frame, “Src and focal adhesion kinase as therapeutic targets in cancer,” Current Opinion in Pharmacology, vol. 8, no. 4, pp. 427–432, 2008.
- A. Abdollahi, D. W. Griggs, H. Zieher et al., “Inhibition of integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy,” Clinical Cancer Research, vol. 11, no. 17, pp. 6270–6279, 2005.
- T. Sethi, R. C. Rintoul, S. M. Moore et al., “Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo,” Nature Medicine, vol. 5, no. 6, pp. 662–668, 1999.
- F. Aoudjit and K. Vuori, “Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells,” Oncogene, vol. 20, no. 36, pp. 4995–5004, 2001.
- F. Thomas, J. M. P. Holly, R. Persad, A. Bahl, and C. M. Perks, “Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor,” Prostate, vol. 70, no. 8, pp. 856–865, 2010.
- J. C. Puigvert, S. Huveneers, L. Fredriksson, M. O. H. Veld, B. Van De Water, and E. H. J. Danen, “Cross-talk between integrins and oncogenes modulates chemosensitivity,” Molecular Pharmacology, vol. 75, no. 4, pp. 947–955, 2009.
- N. Cordes, J. Seidler, R. Durzok, H. Geinitz, and C. Brakebusch, “β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury,” Oncogene, vol. 25, no. 9, pp. 1378–1390, 2006.
- C. C. Park, H. J. Zhang, E. S. Yao, C. J. Park, and M. J. Bissell, “β1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts,” Cancer Research, vol. 68, no. 11, pp. 4398–4405, 2008.
- I. Eke, Y. Deuse, S. Hehlgans et al., “β1 integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy,” Journal of Clinical Investigation, vol. 122, no. 4, pp. 1529–1540, 2012.
- J.-M. Nam, Y. Onodera, M. J. Bissell, and C. C. Park, “Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin α5β1 and fibronectin,” Cancer Research, vol. 70, no. 13, pp. 5238–5248, 2010.
- D. Lane, N. Goncharenko-Khaider, C. Rancourt, and A. Piché, “Ovarian cancer ascites protects from TRAIL-induced cell death through integrin-mediated focal adhesion kinase and Akt activation,” Oncogene, vol. 29, no. 24, pp. 3519–3531, 2010.
- X. H. Yang, L. M. Flores, Q. Li et al., “Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists,” Cancer Research, vol. 70, no. 6, pp. 2256–2263, 2010.